Adamas Pharmaceuticals (NASDAQ:ADMS) Downgraded by Piper Sandler to Neutral

Adamas Pharmaceuticals} stock has undergone multiple analysts rating changes in the recent past.  Adamas Pharmaceuticals Downgraded by Piper Sandler on 10-12-21. In a note to investors, the firm issued a new rating of Neutral. The analysts previously had rating of Overweight.

View More Adamas Pharmaceuticals (NASDAQ:ADMS) Downgraded by Piper Sandler to Neutral

Adamas Pharmaceuticals (NASDAQ:ADMS) Downgraded by HC Wainwright to Neutral

Adamas Pharmaceuticals} stock has undergone multiple analysts rating changes in the recent past.  Adamas Pharmaceuticals Downgraded by HC Wainwright on 10-12-21. In a note to investors, the firm issued a new rating of Neutral. The analysts previously had rating of Buy.

View More Adamas Pharmaceuticals (NASDAQ:ADMS) Downgraded by HC Wainwright to Neutral

Adamas Pharmaceuticals (ADMS) Downgraded by William Blair to Market Perform

Adamas Pharmaceuticals} stock has undergone multiple analysts rating changes in the recent past.  Adamas Pharmaceuticals Downgraded by William Blair on 10-11-21. In a note to investors, the firm issued a new rating of Market Perform. The analysts previously had rating of Outperform.

View More Adamas Pharmaceuticals (ADMS) Downgraded by William Blair to Market Perform

Adamas Pharmaceuticals (ADMS) Downgraded by JMP Securities to Market Perform

Adamas Pharmaceuticals} stock has undergone multiple analysts rating changes in the recent past.  Adamas Pharmaceuticals Downgraded by JMP Securities on 10/11/2021. In a note to investors, the firm issued a new rating of Market Perform. The analysts previously had rating of N/A.

View More Adamas Pharmaceuticals (ADMS) Downgraded by JMP Securities to Market Perform